Literature DB >> 34453334

A diagnostic confidence scheme for CLN3 disease.

Margaux C Masten1, Camille Corre1, Alex R Paciorkowski1, Amy Vierhile1, Heather R Adams1, Jennifer Vermilion1, Grace A Zimmerman1, Erika F Augustine1,2, Jonathan W Mink1.   

Abstract

Over the past 20 years, diagnostic testing for genetic diseases has evolved, leading to variable diagnostic certainty for individuals included in long-term natural history studies. Using genotype and phenotype data from an ongoing natural history study of CLN3 disease, we developed a hierarchical diagnostic confidence scheme with three major classes: Definite, Probable, or Possible CLN3 disease. An additional level, CLN3 Disease PLUS, includes individuals with CLN3 disease plus an additional disorder with a separate etiology that substantially affects the phenotype. Within the Definite and Probable CLN3 disease classes, we further divided individuals into subclasses based on phenotype. After assigning participants to classes, we performed a blinded reclassification to assess the reliability of this scheme. A total of 134 individuals with suspected CLN3 disease were classified: 100 as Definite, 21 as Probable, and 7 as Possible. Six individuals were classified as CLN3-PLUS. Phenotypes included the classical juvenile-onset syndromic phenotype, a "vision loss only" phenotype, and an atypical syndromic phenotype. Some individuals were too young to fully classify phenotype. Test-retest reliability showed 96% agreement. We created a reliable diagnostic confidence scheme for CLN3 disease that has excellent face validity. This scheme has implications for clinical research in CLN3 and other rare genetic neurodegenerative disorders.
© 2021 SSIEM.

Entities:  

Keywords:  Batten disease; diagnosis; lysosomal disorders; natural history; neurodegenerative disease; neuronal ceroid lipofuscinosis

Mesh:

Substances:

Year:  2021        PMID: 34453334      PMCID: PMC9248362          DOI: 10.1002/jimd.12429

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  41 in total

1.  Rapid diagnostic test for the major mutation underlying Batten disease.

Authors:  I Järvelä; H M Mitchison; P B Munroe; A M O'Rawe; S E Mole; A C Syvänen
Journal:  J Med Genet       Date:  1996-12       Impact factor: 6.318

2.  Batten disease: evaluation of CLN3 mutations on protein localization and function.

Authors:  R E Haskell; C J Carr; D A Pearce; M J Bennett; B L Davidson
Journal:  Hum Mol Genet       Date:  2000-03-22       Impact factor: 6.150

Review 3.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

4.  Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  Erika F Augustine; Heather R Adams; Christopher A Beck; Amy Vierhile; Jennifer Kwon; Paul G Rothberg; Frederick Marshall; Robert Block; James Dolan; Jonathan W Mink
Journal:  Dev Med Child Neurol       Date:  2014-11-11       Impact factor: 5.449

Review 5.  Human pathology in NCL.

Authors:  Glenn W Anderson; Hans H Goebel; Alessandro Simonati
Journal:  Biochim Biophys Acta       Date:  2012-11-29

6.  Brain MRI abnormalities and spectrum of neurological and clinical findings in three patients with proximal 16p11.2 microduplication.

Authors:  Isabel Filges; Steven Sparagana; Michael Sargent; Kathryn Selby; Kamilla Schlade-Bartusiak; Gregg T Lueder; Amy Robichaux-Viehoever; Bradley L Schlaggar; Joshua S Shimony; Marwan Shinawi
Journal:  Am J Med Genet A       Date:  2014-05-28       Impact factor: 2.802

7.  Heterogeneity of late-infantile neuronal ceroid lipofuscinosis.

Authors:  N Zhong; D N Moroziewicz; W Ju; A Jurkiewicz; L Johnston; K E Wisniewski; W T Brown
Journal:  Genet Med       Date:  2000 Nov-Dec       Impact factor: 8.822

Review 8.  Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.

Authors:  Maria Kousi; Anna-Elina Lehesjoki; Sara E Mole
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.700

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 10.  The CLN3 gene and protein: What we know.

Authors:  Myriam Mirza; Anna Vainshtein; Alberto DiRonza; Uma Chandrachud; Luke J Haslett; Michela Palmieri; Stephan Storch; Janos Groh; Niv Dobzinski; Gennaro Napolitano; Carolin Schmidtke; Danielle M Kerkovich
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.